Thursday, December 18, 2008

Cough Drug Ingredient May Treat Prostate Cancer

A study published today in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer. Researchers found that noscapine, which has been used in cough medication for nearly 50 years, reduced tumor growth in mice by 60% and limited the spread of tumors by 65% without causing harmful side effects.

Prostate cancer is the most common cancer among men in the United States. The American Cancer Society estimates that 186,320 men will be diagnosed with prostate cancer in 2008 and 28,660 will die from it. One man in 6 will get prostate cancer during his lifetime. Although slow-growing in most men, the cancer is considered advanced when it spreads beyond the prostate. There is no known cure. And low income men are at an increased risk of advanced prostate cancer

Noscapine is a naturally-occurring substance, a non-addictive derivative of opium found in cough medicines. As a natural substance, noscapine cannot be patented, which has limited the potential for clinical trials.

Hormone therapy and chemotherapy, along with radiation and surgery, are currently used to slow the progression of advanced prostate cancer. Side effects resulting from these treatments include impotence, incontinence, fatigue, anemia, brittle bones, hair loss, reduced appetite, nausea and diarrhea. No toxic side effects were observed in the laboratory study of noscapine.

Find the story at EurekaAlert!

Posts, Possibly of Interest

Phony Patients may Avert Adverse Drug Events

Smoking May Up Colorectal Cancer Risk & Death

2009: Top 9 Issues for Health Industries

No comments: